Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Scientific presentation

Single-cell Multi-omics and the Horizon of Clinical Utility

Aaron Llanso

 The Tapestri Single-cell Measurable Residual Disease (scMRD) Assay for AML is the only solution in the market that integrates the genotypic and immunophenotypic assessment of AML MRD across thousands of individual cells, providing clonal insight in tandem with immunophenotype from rare residual disease cells. These high-resolution, integrated molecular profiles bring unprecedented clarity to the complex biology of AML MRD, powering clinically actionable insights. 

The Tapestri scMRD for AML Summit in New York City was a day-long event with industry leaders to discuss the future of single-cell multi-omics in the clinic and beyond. Here, Aaron Llanso, Sr. Director of Clinical Applications, presented “Single-cell Multi-omics and the Horizon of Clinical Utility,” which includes:

  • A brief overview of the Tapestri Platform technology
  • An overview on the clinical opportunities of our scMRD technology
  • A deeper dive into the Tapestri scMRD workflow


Scientific presentation
Single-cell Multi-omics for Discovery, Translational, and Clinical Development
Gema Fuerte, PhD
World CDx Europe (2024)
Scientific presentation
Confidently Validate Cancer Models for Precision Medicine
Dr. Robert Bowman
Divya Rao
Scientific presentation
Unveiling Cellular Complexity: Why & How to Integrate Single-Cell DNA Multi-omics
Brittany Enzmann, PhD
Divya Rao, PhD
Adam Sciambi, PhD
Scientific presentation
Unleashing the Potential of CRISPR & Navigating Heterogeneity in Genome Editing Outcomes
Travis Hardcastle, Synthego
Brittany Enzmann, Mission Bio